Therefore, a single‐arm phase II trial called TUXEDO‐1 enrolled patients with HER2‐positive BC with active BM, and the results showed that T‐DXd still had a remarkable CNS ORR (73.3%).43 Here, ERBB2 is linked to breast cancer.